* Genzyme Corp., of Cambridge, Mass., reported that Seprafilm Bioresorbable Membrane received European CE Mark approval for use in reducing the incidence of adhesions following cardiac surgery. The approval expands the Seprafilm indication in Europe, where it has been used to reduce the incidence of adhesions following abdominal and pelvic surgeries for the last three years.

* Human Genome Sciences Inc., of Rockville, Md., started Phase II studies of its genomics-derived therapeutic protein drug, Keratinocyte Growth Factor-2 (KGF-2). The trials will evaluate its safety and effectiveness as a topical wound healing treatment for venous ulcers. Other Phase II trials for different topical indications are also planned.

* Immucor Inc., of Norcross, Ga., and its wholly owned subsidiary, Gamma Biologicals Inc., received notification that a claim of patent infringement was filed against them relating to the Gamma-ReACT System. The claim, filed in U.S. District Court of the Northern District of Georgia, alleges that Gamma's ReACT System infringes on two related patents granted to Stiftung Fur Diagnostiche Forschung, of Murten, Switzerland, and licensed to co-plaintiff Micro Typing Systems Inc., of Pompano Beach, Fla.

No Comments